S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
FuelCell Is Back To Realistic Valuation
Nigeria's central bank chief arrested after being suspended by president
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I. (Ad)
North Dakota tribe buys idle oil pipeline from Enbridge
Ukrainian President Volodymyr Zelenskyy says ‘counteroffensive, defensive actions’ taking place in war with Russia
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I. (Ad)
Federal regulators promise safety review at all the major freight railroads
Boris Johnson's bombshell exit from Parliament leaves UK politics reeling
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
FuelCell Is Back To Realistic Valuation
Nigeria's central bank chief arrested after being suspended by president
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I. (Ad)
North Dakota tribe buys idle oil pipeline from Enbridge
Ukrainian President Volodymyr Zelenskyy says ‘counteroffensive, defensive actions’ taking place in war with Russia
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I. (Ad)
Federal regulators promise safety review at all the major freight railroads
Boris Johnson's bombshell exit from Parliament leaves UK politics reeling
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
FuelCell Is Back To Realistic Valuation
Nigeria's central bank chief arrested after being suspended by president
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I. (Ad)
North Dakota tribe buys idle oil pipeline from Enbridge
Ukrainian President Volodymyr Zelenskyy says ‘counteroffensive, defensive actions’ taking place in war with Russia
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I. (Ad)
Federal regulators promise safety review at all the major freight railroads
Boris Johnson's bombshell exit from Parliament leaves UK politics reeling
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
FuelCell Is Back To Realistic Valuation
Nigeria's central bank chief arrested after being suspended by president
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I. (Ad)
North Dakota tribe buys idle oil pipeline from Enbridge
Ukrainian President Volodymyr Zelenskyy says ‘counteroffensive, defensive actions’ taking place in war with Russia
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I. (Ad)
Federal regulators promise safety review at all the major freight railroads
Boris Johnson's bombshell exit from Parliament leaves UK politics reeling
NASDAQ:BIOC

Biocept (BIOC) Stock Forecast, Price & News

$1.93
-0.13 (-6.32%)
(As of 06/9/2023 ET)
Compare
Today's Range
$1.91
$2.08
50-Day Range
$1.93
$10.91
52-Week Range
$1.89
$44.10
Volume
73,772 shs
Average Volume
471,755 shs
Market Capitalization
$1.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$120.00

Biocept MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
6,122.5% Upside
$120.00 Price Target
Short Interest
Healthy
1.32% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.46mentions of Biocept in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.03 out of 5 stars


BIOC stock logo

About Biocept (NASDAQ:BIOC) Stock

Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the United States. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, radiation oncologists, urologists, pulmonologists, pathologists, and other physicians; and clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California.

Receive BIOC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biocept and its competitors with MarketBeat's FREE daily newsletter.

BIOC Stock News Headlines

StockNews.com Initiates Coverage on Biocept (NASDAQ:BIOC)
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Biocept Announces Pricing Of $5 Mln Underwritten Public Offering
Biocept shares to commence trading on split-adjusted basis
Biocept Inc BIOC Stock Quote
Biocept (NASDAQ:BIOC) Coverage Initiated at StockNews.com
Biocept (NASDAQ:BIOC) Now Covered by StockNews.com
See More Headlines

BIOC Price History

BIOC Company Calendar

Last Earnings
11/15/2021
Today
6/10/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Diagnostics & Research
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BIOC
Employees
50
Year Founded
1993

Price Target and Rating

Average Stock Price Forecast
$120.00
High Stock Price Forecast
$120.00
Low Stock Price Forecast
$120.00
Forecasted Upside/Downside
+6,122.5%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$-32,090,000.00
Pretax Margin
-564.02%

Debt

Sales & Book Value

Annual Sales
$25.86 million
Book Value
$15.60 per share

Miscellaneous

Free Float
584,000
Market Cap
$1.14 million
Optionable
Optionable
Beta
0.93

Social Links


Key Executives

  • Mr. Samuel D. Riccitelli (Age 64)
    Interim Pres, CEO & Chairman
    Comp: $555.96k
  • Mr. Antonino Morales (Age 67)
    Interim CFO & Director
    Comp: $439.43k
  • Mr. Darrell Taylor Esq. (Age 58)
    Chief Legal Officer, Chief Compliance Officer, Corp. Sec. & Registered In-House Counsel
    Comp: $432.27k
  • Dr. Soon Kap Hahn Ph.D.
    Founder
  • Dr. Philippe J. Marchand Ph.D. (Age 60)
    Chief Operating Officer
  • Mr. Pavel Tsinberg
    Director of Technology Devel.
  • Mr. David S. Moskowitz R.Ph.
    MBA, VP of Strategy & Corp. Communications
  • Dr. Veena M. Singh (Age 48)
    Sr. Medical Director
  • Mr. David Karlander
    Sr. VP of Commercial Operations













BIOC Stock - Frequently Asked Questions

Should I buy or sell Biocept stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biocept in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BIOC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BIOC, but not buy additional shares or sell existing shares.
View BIOC analyst ratings
or view top-rated stocks.

What is Biocept's stock price forecast for 2023?

2 Wall Street analysts have issued 1-year price objectives for Biocept's stock. Their BIOC share price forecasts range from $120.00 to $120.00. On average, they anticipate the company's share price to reach $120.00 in the next year. This suggests a possible upside of 6,122.5% from the stock's current price.
View analysts price targets for BIOC
or view top-rated stocks among Wall Street analysts.

How have BIOC shares performed in 2023?

Biocept's stock was trading at $15.90 at the beginning of 2023. Since then, BIOC stock has decreased by 87.9% and is now trading at $1.9285.
View the best growth stocks for 2023 here
.

When is Biocept's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our BIOC earnings forecast
.

How were Biocept's earnings last quarter?

Biocept, Inc. (NASDAQ:BIOC) posted its quarterly earnings data on Monday, November, 15th. The medical research company reported $0.90 EPS for the quarter, missing the consensus estimate of $2.70 by $1.80. The medical research company earned $17.47 million during the quarter, compared to analyst estimates of $16.87 million. Biocept had a negative trailing twelve-month return on equity of 235.66% and a negative net margin of 32.99%. During the same period in the previous year, the business posted ($12.90) EPS.

When did Biocept's stock split?

Biocept shares reverse split before market open on Wednesday, May 17th 2023. The 1-30 reverse split was announced on Wednesday, May 17th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, May 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What is Michael Nall's approval rating as Biocept's CEO?

4 employees have rated Biocept Chief Executive Officer Michael Nall on Glassdoor.com. Michael Nall has an approval rating of 100% among the company's employees. This puts Michael Nall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at Biocept to a friend.

What other stocks do shareholders of Biocept own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biocept investors own include T2 Biosystems (TTOO), iBio (IBIO), VBI Vaccines (VBIV), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Onconova Therapeutics (ONTX), Walmart (WMT), Inovio Pharmaceuticals (INO) and Acasti Pharma (ACST).

What is Biocept's stock symbol?

Biocept trades on the NASDAQ under the ticker symbol "BIOC."

Who are Biocept's major shareholders?

Biocept's stock is owned by a variety of institutional and retail investors. Top institutional investors include Simplex Trading LLC (0.00%). Insiders that own company stock include David F Hale and David F Hale.
View institutional ownership trends
.

How do I buy shares of Biocept?

Shares of BIOC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biocept's stock price today?

One share of BIOC stock can currently be purchased for approximately $1.93.

How much money does Biocept make?

Biocept (NASDAQ:BIOC) has a market capitalization of $1.14 million and generates $25.86 million in revenue each year. The medical research company earns $-32,090,000.00 in net income (profit) each year or ($64.2642) on an earnings per share basis.

How can I contact Biocept?

Biocept's mailing address is 5810 Nancy Ridge Drive, San Diego CA, 92121. The official website for the company is www.biocept.com. The medical research company can be reached via phone at (858) 320-8200, via email at ir@biocept.com, or via fax at 858-320-8225.

This page (NASDAQ:BIOC) was last updated on 6/10/2023 by MarketBeat.com Staff

My Account -